相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Renal Denervation to Treat Heart Failure
Thomas E. Sharp et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
Are SGLT2 Inhibitors New Hypertension Drugs?
Kazuomi Kario et al.
CIRCULATION (2021)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. An individual participant-level data meta-analysis
Denis Pouchain
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2021)
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
Kazuomi Kario et al.
AMERICAN JOURNAL OF HYPERTENSION (2021)
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Thomas Unger et al.
HYPERTENSION (2020)
Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis Practitioner-Based Nationwide JAMP Study
Kazuomi Kario et al.
CIRCULATION (2020)
Blood Pressure Measurement and Treatment Decisions Masked and White-Coat Hypertension
Kazuomi Kario et al.
CIRCULATION RESEARCH (2019)
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Satoshi Umemura et al.
HYPERTENSION RESEARCH (2019)
Resistant Hypertension Updated Guidelines
Irene Chernova et al.
CURRENT CARDIOLOGY REPORTS (2019)
The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial
Beata Krasinska et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study
Kazuomi Kario et al.
CIRCULATION (2019)
Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics
Kazuomi Kario et al.
HYPERTENSION (2018)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey et al.
CIRCULATION (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2018)
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Robert M. Carey et al.
HYPERTENSION (2018)
Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction
Patrick Rossignol et al.
AMERICAN JOURNAL OF HYPERTENSION (2018)
Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Costas Tsioufis et al.
CURRENT VASCULAR PHARMACOLOGY (2018)
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
Tzung-Dau Wang et al.
HYPERTENSION (2017)
Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis
Hidekatsu Fukuta et al.
HEART FAILURE REVIEWS (2017)
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study
Bryan Williams et al.
HYPERTENSION (2017)
Biological Phenotypes of Heart Failure With Preserved Ejection Fraction
Gavin A. Lewis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction A Multiorgan Roadmap
Sanjiv J. Shah et al.
CIRCULATION (2016)
Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials
Chunbin Wang et al.
HEART LUNG AND CIRCULATION (2016)
Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study
Claudio Borghi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction
Phillip D. Levy et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
Rohan Samson et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Paul Muntner et al.
HYPERTENSION (2014)
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
Kazuomi Kario et al.
HYPERTENSION (2014)
Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study
Costas Tsioufis et al.
JOURNAL OF HYPERTENSION (2014)
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension
Steven M. Smith et al.
JOURNAL OF HYPERTENSION (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
Dharam J. Kumbhani et al.
EUROPEAN HEART JOURNAL (2013)
Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network
Brent M. Egan et al.
HYPERTENSION (2013)
Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients
Stacie L. Daugherty et al.
CIRCULATION (2012)
Spironolactone Prevents Chlorthalidone-Induced Sympathetic Activation and Insulin Resistance in Hypertensive Patients
Prafull Raheja et al.
HYPERTENSION (2012)
Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Brent M. Egan et al.
CIRCULATION (2011)
Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring
Alejandro de la Sierra et al.
HYPERTENSION (2011)
Prevalence of Resistant Hypertension in the United States, 2003-2008
Stephen D. Persell
HYPERTENSION (2011)
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk
Ajay K. Gupta et al.
JOURNAL OF HYPERTENSION (2011)
Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study
Yuichiro Yano et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Prognostic Value of Nocturnal Blood Pressure Reduction in Resistant Hypertension
Elizabeth Silaid Muxfeldt et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension
Gil F. Salles et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension
SD Pierdomenico et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Epidemiology, aetiology, and prognosis of heart failure
JJ McMurray et al.
HEART (2000)
分享论文
